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developing risk adjustment mortality models. The in-hospital moriality in SVG PCI is reli- 
ably predicted by incorporating only a few clinical variables known prior to Starting the 
procedure. The ability to accurately assess risk will aid in patient counseling and case 
selection. 
1028-14 Does the Beneficial Effect of Distal Protectlon in 
Saphenous Vein Graft Interventions Vary With Lesion 
Length? A SAFER (Saphenous Vein Graft Angioplasty 
Free of Emboli Randomized) Substudy 
Greoorv Ft. Giuolia, Ross Prpic. Donald E. Cutlip. Jeffrey J. Popma. Kalon L. Ho, 
Laura Mauri, Unsal Kaya, Dennis Wahr, Barry George, Donald S. Bairn. Richard E. 
Ku&, Harvard Clinical Research Institute, Boston, Massachusetts. St. Joseph Mercy 
Hospital, Ann Arbor, Michigan. 
Background: The SAFER trial demonstrated a dramatic reduction in Major Adverse 
Clinical Events (MACE: a composite of death, Ml or revascularfzation) acutely and at 30 
days following saphenous vein graft (SVG) percutaneous intervention (PCI) with the use 
of the Percusurge GuardWire TM distal protection device. This benefit was anributed to 
the prevention of distal migration of atherosclerotic debris with the device. 
Methods: We sought to evaluate if the reduction in MACE seen in the SAFER trial varied 
with the length of the treated lesion. We divided lesion lengths into quartiles and per- 
formed a stratified analysis to evaluate for effect modification by lesion length on the 
reduction in MACE with the GuardWireTM compared to patients treated with no distal pro- 
tection. 
Rasutts: Of the 751 lesions treated, longer lesions were associated with a higher inci- 
dence of MACE in both the control group (p=O.Oll) and GuardWireTM group (p=O.OOl). 
As demonstrated in the table, use of the GuardWireTM was associated with a reduction in 
MACE in each quartile of lesion length. With multivariable modeling, shorter lesions 







N 30.Day 30-Day Odds Ratio Relative P-value 
MACE MACE (95% Cl) Reduction 
Without With MACE 
GuardWire GuardWire 
166 23% 16% 0.72 22% 0.47 
(0.36-l .48) 
14.8-22 197 15% 10.5% 0.65 30% 0.39 
(0.28-l .52) 
10-14.6 167 17.2% 6.5% 0.45 51% 0.06 
(0.16-1.10) 
<lo 179 6.1% 2.2% 0.25 73% 0.09 
(0.05-l .26) 
Conclusion: The reduction in MACE seen with GuardWireTM occlusion balloon distal 
protection in SVG PCI is upheld regardless of the length of lesion being treated. There is 
a trend toward more relative benefit with the GuardWlreTM for shorter lesions despite the 
finding that shorter lesions convey a lower risk of MACE. 
1028-15 Supported Elective Angioplasty Procedures Without 
On-Site Cardiac Surgery Is Associated With Low Risk of 
Adverse Events 
KirkN.Garran, Henry T. Tmg, Mandeep Singh, Ryan J. Lennon, Katherine L. Boutchee, 
Joseph A. Dearani. Jack T. Cusma, Douglas L. Wood, David R. Holmes, Jr., Mayo Clinic, 
Rochester, Minnesota. 
Background: The safety of elective percutaneous coronary intervention (PCI) at commu- 
nity hospitals without on-site cardiac surgery is uncertam. 
Methods: A cooperative plan to support PCI was implemented by Mayo Clinic cardiolo- 
gists and cardiac surgeons at Saint Marys Hospital (SMH, tertiary care facility) and 
lmmanuel St Joseph’s Hospital (ISJ, no cardiac surgery). These hospitals are separated 
by 65 miles. Patient selection criteria (ACClAHA type A or Bl lesion type), contingently 
plans and a telecommunications network to support consultation between physicians and 
surgeons during PCI were developed. Success and complications observed at ISJ over 
the first 26 months of operation were compared to pts treated at SMH, matched for lesion 
type. Expected mortality risk was estimated using the New York State angioplasty data- 
base. 
Results: Between 3/99 and 7/01, elective PCI was performed in 206 pts at ISJ (stents in 
94.6%) and 690 similar pts at SMH @tents in 66.4%). Unmatched variables were similar, 
except SMH pts had more severe angina, myocardial injury, prior bypass surgery or heart 
failure. Abciximab was used in 76% ISJ and 23% SMH pts (p<O.OOl). Procedures were 
successful in 99.5% ISJ and 97.2% SMH pts (p=O.O53). No patient required transport for 
urgent cardiac or vascular surgery. Table shows estimated and observed mortality at 
both hospitals. 
Follow-up for at least 6 months showed no differences in late outcomes. 
Conclusions: Supported elective PCI in selected low risk patients is safe. On-site cardiac 
surgical services may no longer be required. 
Location Expected Deaths Actual Deaths CABG 
SMH (n=690) Frequency 11.0 5 3 
Percent (95% C.I.) 1.60 (0.9, 2.9) 0.72 (0.2, 1.7) 0.43 (<O.l, 1.3) 
ISJ (n=206) Frequency 2.7 1 0 
percent (95% C.I.) 1.30 (0.4, 4.2) 0.49 (<O.l, 2.7) 0.00 (0, 1.8) 
1028-I 6 Percutaneous Interventions of the Internal Mammary 
Artery GraR: Immediate and Long-Term Clinical 
Outcome 
BBoccalane, Paulino Sousa, Remy Choussat. Bruno Farah. Rossella Gonilla, Jean 
Fajadet, Jean Paul Bouhnoure, Jean Marco, Clinique Pasteur. Toulouse, France 
Background: Safety of percutaneous treatment of the internal mammary artery (IMA) 
graft has been reported in small numbers of patients series. However, information is 
needed regarding utility of stent implantation. radial approach and long term clinical out- 
comeMethods: We report the immediate results and long-term clinical outcome of per- 
cutaneous coronary intervention (PCI) of the IMA graft. Between June 1995 and June 
2000,136 consecutive pts underwent PCI of the IMA graft, by either balloon angioplasty or 
stenting. These procedures represent 0.9 % of the 9649 PCI procedures performed in 
our institution in this period. We analysed clinical and procedural predictors of survival 
and event-free survival defined as freedom from death, myocardial infarction and target 
vessel coronary revascularization. Results: Clinical Follow-up ( mean 41.3k17.6 
months) was obtained in all the patients. The procedure was performed by radial 
approach in 39 and by femoral approach in 49. IMA graft was Len for 60 PTS and Right 
for 26 PTS. A total of 93 lesions (76 located at the distal anastomosis, 9 at the body of 
the graft and 6 at the ostium) were treated: 61 by balloon, 29 by stenting after predilata- 
tion and 3 by direct stenting. Mean lesion length, reference vessel diameter and prepro- 
cedural percentage of stenosis were 11.22 6.2 mm, 2.6+0.4 mm and 61+ 6 96 
respectively. Procedural success was achieved in all patients. In-hospital MACE included 
only one Cl wave myocardial infarction. Three years overall survival was 90.6 * 4.3% 
(mean f SEE) and event free survival 67.9+4.2%. At 1 and 3-years follow-up, freedom 
from any coronary revascularization was 67.3+4.2% and 61.9*5.1% respectively. Neither 
lesion location on the graft, nor stem implantation were found to be independent predic- 
tors of cardiac events at follow-up.Conclusfons: This report suggests that PCI of IMA 
graft, performed by radial or femoral approach, is associated with low procedural risk and 
satisfactory long term clinical outcome and can be an effective alternative to surgery. 
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1029-17 FGF-1 Gene Therapy Plasmid for Patients With Critical 
Limb Ischemia: Final Results 
SD. Anthony Comerota, Nicolas Chronos, John Laird, Rafael Sequeira, 
Bruce Konke, Craig Kent, Juha-Pekka Salenius, Maria Pyle, Richard Pilsudski, Hennepin 
County Medical Center, Minneapolis, Minnesota, University of Minnesota, Minneapolis, 
Minnesota. 
Angiogenic growth factors represent a novel treatment for patients (Pts) with critical limb 
&hernia (CLI) who are not amenable to standard revascularization. We evaluated the 
safety and tolerability of increasing doses of IM delivery of a nonviral plasmid encoding 
fibroblast growth factor (NVlFGF) in Pts with CLI. Methods: 51 Pts with CLI (rest pain 
and/or non-healing ulcers) and not eligible for revascularization based on angiography < 
1 month were randomized to receive IM NVlFGF into the ischemic thigh and calf. 27 Pts 
received 1 treatment (500 to 16,000 ug.) and 24 pts received 2 treatments at 0 and 3 
weeks (5OQ to 6000 ug x2). FGF-1 levels, plasmid bicdistribution, transcutaneous oxygen 
(TcPO& ankle brachial index (ABI), pain assessment by a visual analog scale, and ulcer 
healing were assessed at baseline, 2 , 3 , and 6 months. Results: For the 33 completed 
Pts (Final results ll/Ol), NVlFGF was well tolerated with no serious adverse side effects 
related to the NVlFGF including no death, myocardial Infarction, or cancer. FGF-1 was 
not detected and there was only limited and transient biodistribution of plasmid in 
plasma. A significant reduction was noted in pain and ulcer size. with a significant 
increase in TcP02 and a trend for ABI compared to baseline values (see table). Conclu- 
sion: In the first trial using FGF gene therapy for Pts with CLI. NV1 FGF was well tolerated 
with encouraging initial clinical results. These results suppolt a randomized, double blind, 
placebo controlled trial in Pts with CLI using NV1 FGF. 
Change from BL 
(p=) 
2 Months 
3 Months 
6 Months 
Pain 
-51 
(.OOOl) 
-50 
(.OOOl) 
-60 
(.OOOl) 
Ulcer Size 
NA 
NA 
-53% 
(.002) 
TcPO2 
d2 
(.OOl) 
+16 
(.OOOl) 
Not Done 
ABI 
+0.07 
(.007) 
+0.09 
(.005) 
CO.08 
(.07) 
